GAMMA Investing’s MBX Biosciences MBX Stock Holding History

GAMMA Investing’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$23.6K	Buy	402 +98	+32%	+$6.14K	﹤0.01%	2841
2026 Q2	$16.8K	Buy	304 +5	+2%	+$175	﹤0.01%	2939
2026 Q1	$8.93K	Hold	299	–	–	﹤0.01%	3123
2025 Q4	$9.43K	Hold	299	–	–	﹤0.01%	3006
2025 Q3	$5.23K	Hold	299	–	–	﹤0.01%	3158
2025 Q2	$3.41K	Buy	299 +279	+1,395%	+$2.84K	﹤0.01%	3251
2025 Q1	$148	Buy	+20	New	+$211	﹤0.01%	3769

Other funds holding MBX

AWA

Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return

KWM

Koa Wealth Management Encinitas, California $154M AUM 13.16% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's MBX Position: Q3 2026 in Review

GAMMA Investing increased its MBX Biosciences (MBX) stake by 32% in Q3 2026, buying an estimated $6.14K and bringing the position to 402 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2841.

GAMMA Investing first reported a position in MBX in Q1 2025 and has held it in 7 quarters since. 9 funds tracked by Wall St. Rank hold MBX as of Q3 2026.

GAMMA Investing held 402 shares of MBX Biosciences worth $23.6K as of Q3 2026.
GAMMA Investing bought 98 MBX Biosciences shares in Q3 2026, an estimated $6.14K.
MBX Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2841 holding.
GAMMA Investing first reported a position in MBX Biosciences in Q1 2025 and has held it in 7 quarters since.
9 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.